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Introduction: Premature cardiovascular events have been observed in systemic lupus erythema-
tosus (SLE) patients, but the reason for this accelerated process is still debatable; although 
traditional risk factors are more prevalent in such patients than in the general population, they 
do not seem to fully explain that enhanced risk. One of the most important conditions is a pro-
atherogenic lipid proile. There is not enough data about it in Mexican SLE patients.
Objective: To establish the differences in the lipid proiles between Mexican patients with SLE 
and the general population. 
Material and methods: Observational, transversal, descriptive and comparative study, between 
SLE patients and age-sex-matched healthy volunteers. We performed a full lipid proile (by 
spectrophotometry) 14 hours of fast. The results obtained were analyzed by the statistical pro-
gram SPSS® Statistics version 17. 
Results: We studied the full lipid proiles of 138 subjects, 69 with a diagnosis of SLE and 69 age-
sex-matched healthy volunteers; 95.7% were females and 4.3% males. Average age was 30 years; 
average body mass index (BMI) 25.96 ± 5.96 kg/m² in SLE patients and 26.72 ± 4.36 kg/m² in the 
control group (p = 0.396). Average of total cholesterol 156 mg/dl in the SLE patients and 169.4 
mg/dl in the control group (p = 0.028); average of low density lipoprotein (LDL) cholesterol 
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Introduction
Premature cardiovascular events have been observed in sys-
temic lupus erythematosus (SLE) patients, but the reason 
for this accelerated process is still debatable.1
In addition to traditional cardiovascular risk factors in SLE 
patients, there are factors inherent to the disease such as: 
immune complex-induced endothelial damage, vasculitis, 
thrombosis associated with antiphospholipid antibodies, Lib- 
man Sacks´ endocarditis, renovascular hypertension, glo-
merulonephritis and corticosteroid therapy used as part of 
the disease treatment.1
A greater prevalence of dyslipidemia has been reported in 
these patients, inding a marked pro-atherogenic lipid proi-
le, i.e., elevation low density lipoprotein (LDL), lipoprotein 
(a), triglycerides and free fatty acids, as well as reduction of 
high density lipoproteins (HDL).2 Amongst traditional cardio-
vascular risk factors, dyslipidemia is considered to represent a 
greater impact on the development of cardiovascular disea-
se, in addition to being related to a higher renal morbidity 
and a higher mortality in SLE patients.3 
Chronic use of glucocorticoids, as part of the treatment 
of this pathology, also favours the development of a pro- 
atherogenic lipid proile in this population. Additionally, fre-
quently used immunosuppressants for SLE treatment positi-
vely correlate with the antioxidant and antiinlammatory 
ability, reporting an oxidized LDL reduction (LDLox) in pa-
tients who receive them.4
About 75% of SLE patients develop hypercholesterolemia 3 
years after diagnosis; these patients report the highest ra-
tes of cardiovascular events.5 In patients with more than 
5-year of diagnosis progression, the risk of acute myocardial 
infarction has been reported to increase up to 52 times.6
For the above mentioned reasons, we decided to analyze 
and establish the differences in the lipid proiles between 
Mexican patients with SLE and the general population, mat-
ched by age and gender. 
Material and methods
We performed an observational, transversal, descriptive 
and comparative study. We included 69 patients diagnosed 
with SLE by a rheumatologist, meeting at least 4 classiica-
tion criteria of the American College of rheumatology, mo-
diied in 1997.7 The patients were 18 years of age or older, 
had no known cardiovascular history (myocardial infarction, 
angina, stroke, transient ischemic attack), attended by a 
rheumatologist in “Dr. José Eleuterio González” University 
Hospital and agreed to participate through a signed infor-
med consent. This study was approved by our local Ethics 
Committee (MI09-007).
Subsequently, the patients were matched with 69 healthy 
volunteers by age and gender; subjects without any autoim-
mune diseases and no known cardiovascular pathologies at 
the randomization. All subjects (138) were required to com-
ply with a 14-hour fast, following which a venipuncture 
was performed to obtain a full lipid proile, using the spec-
trophotometry technique. In addition, the following tests 
were done: erythrocyte sedimentation rate using the Win-
trobe method, ultra-sensitive C-reactive protein (CrP), 
Complete Blood Count in the same lab.
We compared the total cholesterol value, LDL, HDL and 
triglycerides; then, we identiied pro-atherogenic characte-
ristics in the lipid proile, establishing as a cut-off point in 
accordance with that described in the literature as a cardio-
vascular risk factor: total cholesterol > 200 mg/dl, triglyce-
rides > 150 mg/dl, HDL < 45 mg/dl, LDL > 100 mg/dl. We 
obtained the BMI of all patients.
Results were analyzed using the statistical program SPSS 
v17, performing a descriptive analysis for demographic and 
clinical variables. 
For the binominal variable contrast, we used chi-square 
test or Fisher’s exact test, with 2 x 2 contingency tables; for 
non-parametric variables we used the Mann-Whitney U test. 
p ≤ 0.05 was taken as a signiicant value.
Results
We analyzed 69 SLE patients and 69 healthy patients, 66 
women (95.7%) and 3 men (4.7%) in each group matched by 
sex and age, with a median age of 30 years, and an inter-
quartile range of 14 (Table 1).
In the lipid proile, we found a total cholesterol average 
of 156 mg/dl in the group of SLE patients compared to 169.4 
mg/dl in the control group (p = 0.028). The higher mean is 
in the group of healthy individuals, with a statistically signi-
icant difference. As far as LDL cholesterol levels, we found 
an average of 85.27 mg/dl in the group of SLE patients while 
in the group of healthy subjects the mean was 97.57 mg/dl 
(p = 0.023), also with a statistically signiicant difference. 
Despite inding statistically signiicant differences for abso-
lute igures of total cholesterol and LDL cholesterol; when 
we performed the analysis for pro-atherogenic characteris-
tics we did not ind any statistically signiicant differences 
between both groups (Table 2).
In addition, we analyzed other clinical and biochemical 
parameters (BMI, erythrocyte sedimentation rate, albumin, 
CRP, uric acid, glucose and hemoglobin), inding that data in 
the group of patients regarding the erythrocyte sedimenta-
tion rate, CRP and serum creatinine were higher with statisti- 
cal signiicance. On the other hand, the healthy volunteers 
85.27 mg/dl in the SLE patients and 97.57 mg/dl in the control group (p = 0.023). 
Conclusions: We did not ind statistical differences in the lipid proiles among patients and 
healthy volunteers, which could explain increased cardiovascular morbidity and mortality ob-
served in SLE patients. 
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group had higher hemoglobin, lymphocytes, platelets, al-
bumin and glucose, also with statistical signiicance (Table 
2). 
In the 69 SLE patients, we also analyzed the disease’s cha-
racteristics; inding that the average number of years of SLE 
diagnosis at the time of entering the study was 5 years; with 
an interquartile range of 8, this population had an average 
diagnostic age of 25.8 ± 7.41 years. The disease activity in-
dex used was the MEX-SLEDAI, inding an average of 1.69 ± 
2.71, which places the average of the population in the low 
activity group.
Concerning medication use, we found that 68 patients 
(97.1%) used antimalarials at the time of the study; 20 pa-
tients (29.4%) were taking chloroquine at an average dosage 
of 150 mg/day, while 48 patients (70.5%) were taking hydro-
xychloroquine at an average dosage of 200 mg/day. Sixty 
patients (88.2%) had been taking antimalarials routinely for 
over a year.
Discussion
We found the difference in total cholesterol and LDL avera-
ges to be statistically signiicant; however, it was signii-
cantly greater in the healthy group, which may be explained 
by the genetics that our Mexican population carries for dys-
lipidemia. Thus, we compared BMI between both groups and 
lipid proiles, inding no statistically signiicant differences.
When we analyzed atherogenic lipid levels, thus identifying 
cardiovascular risk, we found no differences between the li-
pid proiles from the SLE patients and the healthy volunteers. 
This suggests that there may be qualitative differences rather 
than quantitative ones in lipids of SLE patients.
In SLE patients, an increase in hydroperoxidized lipids as-
sociated with endothelial dysfunction has been reported, as 
well as a decrease in antioxidizing ability.8 High oxidized 
HDL levels (HDLox), not only eliminate the protecting effect 
of HDL, but also are associated with pro-inlammatory ac-
tion and accelerated atherogenesis.2 IgG-type antibodies 
against LDLox are also linked with the early development of 
atherosclerosis observed in SLE patients.8
One of the weaknesses in our work is the fact that we did 
not measure LDLox levels. Increased cardiovascular risk, 
which in recent years has been found in SLE patients, in this 
studied population is not consistent with a pro-atherogenic 
lipid proile; however, further studies including larger num-
ber of patients are required to determine the causes that 
lead to an increase in cardiovascular morbimortality in this 
speciic population.
In our Mexican population with SLE, we were not able to 
ind a marked atherogenic proile, contrary with the recent 
published.3 However, in this last publication they studied 
Caucasian, Black and Asian races but did not include the 
Latin American population. Additionally, in this group cha-
racteristics associated with total cholesterol increase were 
age over 30 years and use of prednisone, with dosages grea-
ter than 10 mg/day. In the population studied by Petri et 
al., 35% of the patients used hydroxichloroquine on a regu-
lar basis, unlike our population in which 97.1% were taking 
anti-malarials. This is relevant because the use of hydro-
xychloroquine has been linked to an improvement in lipid 
proiles of SLE patients.9
In a study performed in India including 30 SLE patients 
paired by sex and age with 30 control subjects, dyslipide-
mia was found in 63% of SLE patients; however, a statisti-
cally signiicant difference was only found in triglycerides, 
which turned out to be greater in the SLE group.10 In the 
same study, 63% of SLE patients had been diagnosed with 
lupus nephropathy, which could have altered lipid charac-
teristics in that population in contrast with our population, 
in which they found only 12% of lupus nephropathy (none 
with proteinuria in nephrotic range nor undergoing renal 
replacement therapy, when subjects were included in the 
study).
In a trial including Mexican subjects, in which 16 SLE pa-
tients were studied, no difference was found in the lipid 
profile of SLE patients, compared to a healthy control 
group, paired by age, sex and BMI. However, one advantage 
of our study was that did include a larger number of pa-
tients and controls.11
The few studies performed in a Mexican population regar-
ding the lipid proile in SLE patients, make it indispensable 
to conduct further studies on the issue. The differences 
found about hemoglobin, erythrocite sedimentation rate, 
albumin, CrP, albumin, creatinine, platelets and lympho-
cytes, may be explained as expected changes in SLE pa-
tients. 
Another important consideration is that the SLE patient 
sample had a low MEX-SLEDAI (under 2, on average), which 
places them in the subgroup of low-activity patients, the 
disease activity being another variable frequently associa-
ted with accelerated atherosclerosis; however, in our popu-
lation did not keep a relationship with the disease activity.12 
Table 1 Clinical characteristics of the studied population. Monterrey, N. L., Mexico, 2011.
Characteristic SLE Volunteers p
Gender
• Male n (%)






Median age in years (interquartile range) 30 (14.0) 30 (14.0) 1.000
Framingham’s Score ± SD 1.63 ± 1.48 1.43 ± 0.977 0.771
Body mass index ± SD 25.96 ± 5.93 26.72 ± 4.36 0.396
SD: standard deviation; SLE: systemic lupus erythematosus.
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As for other traditional cardiovascular risk factors (obesi-
ty, hypertension, hyperglycemia after fasting),12 no link with 
lipid proile alterations was found. However, this could be 
related to our patients’ age at the time of inclusion in the 
study (mean 30 years); at this age, cardiovascular comorbi-
dities are less prevalent. 
Conclusions
We did not find statistical differences in the lipid profiles 
among patients and healthy volunteers to explain the increa-
sed cardiovascular morbimortality observed in SLE patients. 
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